BCAX — Bicara Therapeutics Inc. price, chart and key statistics

Price data

Price

$18.35

YTD price return

+9.03%

YTD total return

+9.03%

Next earnings

Nov 9, 2026

Market cap

1.2B2024-09 1.4B2026-10 1.2B-12.4% over the window

Enterprise value

801.2M

Shares outstanding

66.2M2023-12 640.4K2026-06 66.2M+10233.3% over the window

52W low

$13.70

52W high

$30.99

From 52W high

-40.79%

From 52W low

+33.94%

52W range

27%

Volume

Rel volume

0.63×

30D volume

779.7K

30D $ vol

14.9M

Fundamentals

EPS (ttm)

-$2.732023-12 -$89.612026-06 -$2.73-97.0% over the window

FCF (ttm)

-135.2M2023-12 -46.2M2026-06 -135.2M+192.7% over the window

FCF/share

-$2.042023-12 -$72.172026-06 -$2.04-97.2% over the window

Book value/share

$7.082023-12 -$232.312026-06 $7.08-103.0% over the window

ROE

-39.54%2024-12 -13.8%2026-06 -39.5%+186.1% over the window

ROA

-36.19%2023-12 -22.2%2026-06 -36.2%+62.9% over the window

Current ratio

11.592023-12 15.322026-06 11.59-24.3% over the window

Growth (CAGR, ttm) · 10Y

Shares

+21.29%2025-06-30 → 2026-06-3054.6M → 66.2M (+21.3% total)+540.75%2023-12-31 → 2026-06-30640.4K → 66.2M (+10233.3% total)n/an/a

Per-share growth (CAGR, ttm) · 10Y

Book value/share

-11.19%2025-06-30 → 2026-06-30$7.98 → $7.08 (-11.2% total)n/an/an/a

Price

+12.86%2025-10-20 → 2026-10-20$16.26 → $18.35 (+12.9% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.n/an/an/a

Total return

+12.86%2025-10-20 → 2026-10-20$16.26 → $18.35 (+12.9% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.n/an/an/a

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.

-6.7×2024-09 -26.662026-10 -6.55-75.4% over the window

Fwd P/E

-5.2×

P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.

2.6×2024-09 2.722026-10 2.59-4.8% over the window

FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.

-11.14%2024-12 -7.9%2026-06 -6.9%-12.6% over the window

Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 66.2M ÷ 54.6M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.

-21.29%

Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (-21.29%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($506.9M). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.

-21.29%

Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($-191.3M) ÷ today's market cap ($1.2B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.

-15.75%2024-12 -35.0%2026-06 -9.7%-72.2% over the window

Shareholder yield (cash, ttm)(TTM buybacks net of issuance $-191.3M + TTM dividends $0) ÷ today's market cap ($1.2B). Same caveat as the cash buyback yield.

-15.75%2024-12 -35.0%2026-06 -9.7%-72.2% over the window